Price alert —
Sign in to get a one-time email the moment FMS crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · FMS
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $4.6B | $0.1B | $0.4B | $0.0B | 2.5% | 8.1% |
| 2025-12-31 | $5.1B | $0.3B | $0.5B | $0.6B | 6.5% | 10.8% |
| 2025-09-30 | $4.9B | $0.3B | $0.5B | $0.5B | 5.6% | 10.3% |
| 2025-06-30 | $4.8B | $0.2B | $0.4B | $0.6B | 4.7% | 8.2% |
| 2025-03-31 | $4.9B | $0.2B | $0.4B | $0.0B | 3.1% | 7.8% |
Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.
Compare FMS vs peers
Line FMS up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
Add tickers to compare with FMS
~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.
Earnings replay · last 20 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
| Date | EPS actual | EPS est | Surprise | Next-day |
|---|---|---|---|---|
| 2026-05-03 | 0.46 | 0.50 | -8.6% | +0.7% |
| 2026-02-24 | 0.72 | 0.55 | +30.0% | -0.0% |
| 2025-11-04 | 0.55 | 0.50 | +9.1% | -0.2% |
| 2025-08-05 | 0.46 | 0.47 | -2.4% | -3.7% |
| 2025-05-06 | 0.42 | 0.38 | +9.7% | +3.0% |
| 2025-02-24 | 0.46 | 0.40 | +13.6% | +0.6% |
| 2024-11-05 | 0.41 | 0.35 | +16.0% | +3.7% |
| 2024-07-30 | 0.35 | 0.34 | +3.4% | -1.7% |
| 2024-05-07 | 0.32 | 0.25 | +29.9% | +2.8% |
| 2024-02-20 | 0.44 | 0.30 | +46.4% | -6.3% |
| 2023-11-01 | 0.28 | 0.31 | -8.1% | +3.3% |
| 2023-08-02 | 0.30 | 0.28 | +5.4% | +2.0% |
| 2023-05-08 | 0.18 | 0.12 | +50.2% | -0.1% |
| 2023-02-22 | 0.24 | 0.22 | +8.3% | -4.5% |
| 2022-10-31 | 0.21 | 0.34 | -37.3% | -1.3% |
| 2022-07-28 | 0.39 | 0.43 | -10.5% | -4.1% |
| 2022-05-04 | 0.34 | 0.26 | +30.8% | -0.1% |
| 2022-02-22 | 0.39 | 0.43 | -9.9% | -4.4% |
| 2021-11-02 | 0.47 | 0.44 | +5.8% | -0.9% |
| 2021-07-30 | 0.38 | 0.43 | -12.8% | -2.4% |
Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| FMS ★ | $13B | 13.1 | 6.8 | 0.7 | 9.2 | 0.9 | 26.0% | -5.5% | -17.1% | 12.75% |
| LLY | $1,054B | 42.0 | 26.3 | — | 29.7 | 33.9 | 82.8% | 55.5% | 169.9% | 0.87% |
| UNH | $385B | 31.9 | 18.9 | 0.9 | 17.9 | 3.7 | 19.5% | 0.4% | 61.5% | 5.92% |
| JNJ | $622B | 30.0 | 20.1 | 6.4 | 18.6 | 7.7 | 68.1% | 6.6% | -1.0% | — |
| MRK | $322B | 36.8 | 13.5 | — | 12.1 | 7.0 | 76.7% | 4.9% | — | 4.36% |
| ABBV | $452B | 124.9 | 15.7 | 7.2 | 17.1 | -68.0 | 72.0% | 12.4% | -46.2% | 4.60% |
| PFE | $142B | 19.1 | 8.8 | — | 7.6 | 1.6 | 74.8% | 5.4% | -10.1% | 8.69% |
| TMO | $213B | 31.5 | 21.0 | — | 20.9 | 4.1 | 40.9% | 6.2% | 11.3% | 2.59% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 6.69%
| Holder | Shares | % out |
|---|---|---|
| Pzena Investment Management LLC | 15,052,822 | 3.07% |
| Fiduciary Management, Inc. | 4,462,106 | 0.91% |
| Dodge & Cox Inc. | 3,826,910 | 0.78% |
| Morgan Stanley | 2,484,810 | 0.51% |
| Millennium Management Llc | 1,641,301 | 0.33% |
| Brandes Investment Partners L.P. | 1,610,849 | 0.33% |
| Todd Asset Management LLC | 1,296,543 | 0.26% |
| TEACHERS RETIREMENT SYSTEM OF THE ST | 816,200 | 0.17% |
| Goldman Sachs Group Inc | 818,002 | 0.17% |
| Integral Health Asset Management, LL | 775,000 | 0.16% |
Insider activity · 90d
No insider trades for FMS in last 90d.
Analyst estimates
FinnhubWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
No filings available.
About FMS
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company operates through Care Delivery and Care Enablement segments. It also develops, manufactures, and distributes various health care products, including hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at hom…
Options picks · FMS
ITM + OTM ideas from the latest scanLoading…
Congress trades · FMS
STOCK Act disclosuresLoading…
SEC filings & insiders · FMS
EDGAR · liveLoading…
Holders · FMS
Institutions & insider activityLoading…